Anti-Mouse LAG-3 Antibody (C9B7W)

[1]Cemerski, S., et al. T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity. j. immunotherapy cancer 3 (Suppl 2), P183 (2015) . |[2]Wang X, et al. Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils. Nat Commun. 2025 Apr 28;16 (1) :3975.|[3]Thudium K, et al. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunol Res. 2022 Oct 4;10 (10) :1175-1189.